Published in Br J Cancer on January 04, 2011
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer (2013) 1.32
Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. J Clin Invest (2013) 1.04
Markers of resistance to anti-EGFR therapy in colorectal cancer. J Gastrointest Oncol (2013) 1.01
Amphiregulin and Epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases. BMC Cancer (2012) 0.99
The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therap Adv Gastroenterol (2013) 0.98
Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res (2014) 0.97
Novel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids. Cancer Res (2014) 0.95
Colorectal Cancer Biomarkers: Where Are We Now? Biomed Res Int (2015) 0.92
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. Br J Cancer (2013) 0.92
Epiregulin: roles in normal physiology and cancer. Semin Cell Dev Biol (2014) 0.91
A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. J Cancer Res Clin Oncol (2012) 0.90
Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. Proc Natl Acad Sci U S A (2012) 0.90
Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol (2011) 0.86
Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer. Contemp Oncol (Pozn) (2013) 0.85
Regulation and roles of bicarbonate transporters in cancer. Front Physiol (2014) 0.85
Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients. Clin Cancer Res (2013) 0.84
Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. Br J Cancer (2012) 0.84
Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS. Onco Targets Ther (2016) 0.83
Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status. Drugs (2015) 0.83
Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Ther (2016) 0.83
Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study. Int J Colorectal Dis (2012) 0.80
Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. Br J Cancer (2016) 0.79
Genetic variations of the A13/A14 repeat located within the EGFR 3' untranslated region have no oncogenic effect in patients with colorectal cancer. BMC Cancer (2013) 0.78
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. Int J Mol Sci (2017) 0.78
Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. Br J Cancer (2016) 0.77
Recent applications of chemosensitivity tests for colorectal cancer treatment. World J Gastroenterol (2014) 0.77
Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. J Cancer Res Clin Oncol (2016) 0.75
Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients. Oncotarget (2016) 0.75
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (2002) 14.20
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol (2008) 10.29
Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci U S A (2002) 9.83
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2009) 7.04
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res (2005) 5.68
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol (2007) 5.68
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res (2007) 5.54
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer (2007) 5.38
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
Epidermal growth factor receptor targeting in cancer. Semin Oncol (2006) 3.84
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer (2009) 3.73
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol (2005) 3.39
Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev (2000) 3.05
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol (2009) 2.92
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol (2008) 2.75
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer (2009) 2.39
Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med (2004) 2.33
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res (2009) 2.25
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol (2007) 2.11
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer (2008) 1.89
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin Cancer Res (2008) 1.80
Biomarker discovery for colon cancer using a 761 gene RT-PCR assay. BMC Genomics (2007) 1.46
Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs (2009) 1.40
Mutation detection by real-time PCR: a simple, robust and highly selective method. PLoS One (2009) 1.29
Responsiveness to cetuximab without mutations in EGFR. N Engl J Med (2005) 1.12
PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. Br J Cancer (2008) 1.07
Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target. J Clin Oncol (2005) 0.81
PTP4A3 expression increases strongly in lymph node metastases from colorectal carcinoma. Anticancer Res (2009) 0.78
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol (1991) 11.09
Remodeling of yeast genome expression in response to environmental changes. Mol Biol Cell (2001) 9.63
Serial regulation of transcriptional regulators in the yeast cell cycle. Cell (2001) 7.99
Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med (1994) 7.05
T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci U S A (1990) 6.19
Negative affectivity: the disposition to experience aversive emotional states. Psychol Bull (1984) 5.93
Toward a consensual structure of mood. Psychol Bull (1985) 5.58
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
Health complaints, stress, and distress: exploring the central role of negative affectivity. Psychol Rev (1989) 4.72
Comorbidity of anxiety and unipolar mood disorders. Annu Rev Psychol (1998) 4.71
Temperament, personality, and the mood and anxiety disorders. J Abnorm Psychol (1994) 4.70
Serum IgM and IgG responses in postnatally acquired rubella. Lancet (1969) 4.16
Outbreak of Vibrio cholerae non-O1 in India and Bangladesh. Lancet (1993) 4.11
Public confidence and cardiac surgical outcome. Cardiac surgery: the fall guy in medical quality assurance. BMJ (1998) 3.77
Measurement of social-evaluative anxiety. J Consult Clin Psychol (1969) 3.72
Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci U S A (1986) 3.68
A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J (1989) 3.62
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene (2000) 3.40
The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells. J Exp Med (1991) 3.35
A gamma-ray burst at a redshift of z approximately 8.2. Nature (2009) 3.29
Positive and negative affectivity and their relation to anxiety and depressive disorders. J Abnorm Psychol (1988) 3.19
ICAM-1 a ligand for LFA-1-dependent adhesion of B, T and myeloid cells. Nature (1988) 3.12
Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. EMBO J (1998) 3.03
B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. J Immunol (1982) 2.93
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med (1989) 2.81
Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab (1973) 2.77
Intra-abdominal and gastrointestinal tuberculosis. Colorectal Dis (2007) 2.70
A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med (1992) 2.57
Measurement of Pseudomonas aeruginosa phenazine pigments in sputum and assessment of their contribution to sputum sol toxicity for respiratory epithelium. Infect Immun (1988) 2.56
The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J Clin Invest (1992) 2.51
Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet (1993) 2.50
CD45 regulates signal transduction and lymphocyte activation by specific association with receptor molecules on T or B cells. Proc Natl Acad Sci U S A (1988) 2.46
Mortality and utilisation of critical care resources amongst high-risk surgical patients in a large NHS trust. Anaesthesia (2008) 2.42
Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity (1998) 2.42
Pyocyanin and 1-hydroxyphenazine produced by Pseudomonas aeruginosa inhibit the beating of human respiratory cilia in vitro. J Clin Invest (1987) 2.40
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol (2010) 2.39
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer (2003) 2.38
An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med (1999) 2.33
Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. J Immunol (1994) 2.31
CD40 stimulation provides an IFN-gamma-independent and IL-4-dependent differentiation signal directly to human B cells for IgE production. J Immunol (1991) 2.28
A human nuclear uracil DNA glycosylase is the 37-kDa subunit of glyceraldehyde-3-phosphate dehydrogenase. Proc Natl Acad Sci U S A (1991) 2.27
Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritis human fluids. Arthritis Rheum (1967) 2.23
Is there a Persian Gulf War syndrome? Evidence from a large population-based survey of veterans and nondeployed controls. Am J Med (2000) 2.23
Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst (1996) 2.21
Temporal shifts in traits of Vibrio cholerae strains isolated from hospitalized patients in Calcutta: a 3-year (1993 to 1995) analysis. J Clin Microbiol (1996) 2.21
Production and characterization of cytotoxic Thy-1 antibody-secreting hybrid cell lines. Detection of T cell subsets. Eur J Immunol (1979) 2.20
Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice. Eur J Anaesthesiol (2007) 2.19
CD22 regulates thymus-independent responses and the lifespan of B cells. Nature (1997) 2.16
Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression. J Immunol (1985) 2.11
Diagnosis and classification of psychopathology: challenges to the current system and future directions. Annu Rev Psychol (1995) 2.11
In situ bioreduction of technetium and uranium in a nitrate-contaminated aquifer. Environ Sci Technol (2004) 2.11
Spread of injectate with superficial cervical plexus block in humans: an anatomical study. Br J Anaesth (2003) 2.05
CD40 signaling activates CD11a/CD18 (LFA-1)-mediated adhesion in B cells. J Immunol (1991) 2.04
Response of critically ill patients to treatment aimed at achieving supranormal oxygen delivery and consumption. Relationship to outcome. Chest (1993) 2.01
Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol (1993) 2.00
Isolation and characterization of antigenic components of a new heptavalent Pseudomonas vaccine. Nat New Biol (1971) 1.98
The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol (1996) 1.94
Facial dyskinesia: a 16-year follow-up study. Br J Psychiatry (1991) 1.94
Inoculation of baboons and macaques with simian immunodeficiency virus/Mne, a primate lentivirus closely related to human immunodeficiency virus type 2. J Virol (1988) 1.91
Manipulating hemodynamics and oxygen transport in critically ill patients. N Engl J Med (1995) 1.91
Safety and efficacy of postoperative epidural analgesia. Br J Anaesth (2001) 1.90
Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc Natl Acad Sci U S A (1985) 1.89
Soluble forms of CD40 inhibit biologic responses of human B cells. J Immunol (1992) 1.88
Some mismatch repair activities in Escherichia coli. Proc Natl Acad Sci U S A (1988) 1.87
CD40 molecules induce down-modulation and endocytosis of T cell surface T cell-B cell activating molecule/CD40-L. Potential role in regulating helper effector function. J Immunol (1994) 1.87
Serum Copper Levels in Pregnancy and Pre-Eclampsia. J Clin Pathol (1949) 1.85
The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst (1993) 1.84
Biochemical quantification of DNA in human articular and septal cartilage using PicoGreen and Hoechst 33258. Osteoarthritis Cartilage (2002) 1.84
Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med (1985) 1.83
Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J Immunol (1994) 1.80
Initial construction of a maladaptive personality trait model and inventory for DSM-5. Psychol Med (2011) 1.78
Colchicine myopathy and neuropathy. N Engl J Med (1987) 1.77
The clinical course and management of thoracic empyema. QJM (1996) 1.76
CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol (1987) 1.76
Both phosphorylation and caspase-mediated cleavage contribute to regulation of the Ste20-like protein kinase Mst1 during CD95/Fas-induced apoptosis. J Biol Chem (2001) 1.76
Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt. J Biol Chem (1999) 1.71
On the role of the platelet membrane skeleton in mediating signal transduction. Association of GP IIb-IIIa, pp60c-src, pp62c-yes, and the p21ras GTPase-activating protein with the membrane skeleton. J Biol Chem (1993) 1.71
A prospective randomised concurrent comparison of the COBE Spectra Version 4.7, COBE Spectra Version 6 (auto PBSC) and Haemonetics MCS+ cell separators for leucapheresis in patients with haematological and non-haematological malignancies. Transfus Apher Sci (2001) 1.68
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
The role of CD40 and CD80 accessory cell molecules in dendritic cell-dependent HIV-1 infection. Immunity (1994) 1.67
Plastic bronchitis occurring late after the Fontan procedure: treatment with aerosolized urokinase. Crit Care Med (2000) 1.66
Oxygen transport patterns in patients with sepsis syndrome or septic shock: influence of treatment and relationship to outcome. Crit Care Med (1997) 1.66
Differential increase of an alternatively polyadenylated mRNA species of murine CD40 upon B lymphocyte activation. J Immunol (1992) 1.66
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res (1999) 1.64
CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. J Immunol (2001) 1.61
First-line Herceptin monotherapy in metastatic breast cancer. Oncology (2001) 1.60
CD22 associates with the human surface IgM-B-cell antigen receptor complex. Proc Natl Acad Sci U S A (1993) 1.60
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol (1994) 1.57
The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol (1985) 1.57
Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J (1988) 1.57
Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323. J Biol Chem (1998) 1.57
Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest (1999) 1.56
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol (1999) 1.56
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Mood and the mundane: relations between daily life events and self-reported mood. J Pers Soc Psychol (1988) 1.56
Antibacterial and antitoxin responses in the serum and milk of cholera patients. Infect Immun (1981) 1.56